Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support


Today in Coagulation/Bleeding Dz...keeping you current

Management of the antiphospholipid syndrome: new approaches
International Journal of Clinical Rheumatology, 10/19/09

Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
Annals of Hematology, 10/23/09

Sickle cell disease and stroke
Blood, 10/13/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address